Novolin 30R is more familiar to many diabetic patients, but more and more patients are switching to Novolac 30, so what is the difference between the two, and what are the benefits of switching to Novolac 30, this issue of WeChat will talk to you about this topic. Gao Hongjiao, Department of Endocrinology, Zunyi First People’s Hospital Novolin 30R contains 30% short-acting human insulin (RI), 70% medium-acting insulin (NPH, low arginine zinc insulin). Novolin 30R is usually injected twice in the morning and evening. After injecting half an hour before breakfast, 30% of short-acting R controls blood sugar after breakfast, while 70% of medium-acting insulin controls blood sugar before and after lunch; after injecting before dinner, it controls blood sugar after dinner and night and morning fasting respectively. Novalax 30 is a biphasic release dosage form of soluble menadione insulin and arginine-conjugated crystalline menadione insulin, which is a mixture of insulin analogues, including 30% menadione insulin and 70% arginine-conjugated crystalline menadione insulin. Soluble menadione insulin can be rapidly absorbed to meet the mealtime insulin requirement, while arginine-conjugated crystalline menadione insulin is released slowly and has a long duration of action to meet the basal insulin requirement, so it is said that Novolin® 30 has the pharmacokinetic characteristics that mimic the mealtime insulin release under normal physiological state. Novalis 30 is closer to the effect of physiological insulin than Novalis 30R. The reason is that human insulin is a 6-membered body, which has to be broken down into a double body and then into a single body to exert insulin action in the body, and the onset of action is long. Menthol insulin is a dimer, so it can take effect as soon as it is broken down into monomers in one step, and the effect time is fast. People generally have their blood sugar rise to peak in 0.5 to 1 hour after meal, and the peak time of Novaline is the same, so Novaline can better simulate physiological insulin secretion and less likely to cause severe and nocturnal hypoglycemic events. In application, Novaline 30R has a long onset of action, so it needs to be injected 30 minutes before a meal. Novalure 30 has a faster onset of action, can be injected immediately before meals, and is less likely to cause hypoglycemia, greatly increasing patient compliance with treatment. A short summary: Novalax 30 is a product developed by Novo to replace Novalax 30R in the future. Compared with human insulin 30R, NovoRx 30 shows: faster absorption, higher plasma insulin concentration, faster and stronger glucose-lowering effect. Of course, in addition to menthol insulin, there are also lysergic insulins, and a variety of premixed insulin analogs have emerged clinically, in addition to NovoRel 50 (premixed menthol insulin 50), Eugenol 25 (premixed lysergic insulin 25), Eugenol 50 (premixed lysergic insulin 50), etc. The difference in the latter figures suggests that the proportion of fast-acting insulin analogs different, and also suitable for different diabetic patients. However, because the onset of action of intermediate-acting insulin (NPH) is 2.5-3h, the peak time is 5-7h, and the duration of action is 13-16h, it does not create the ideal high insulin concentration after Chinese meal, whether it is premixed insulin twice a day (before breakfast and dinner) or premixed insulin analogs, some patients may have higher blood glucose after Chinese meal, and this time can be considered to take oral α-glucose Glucosidase inhibition or glargine type insulin secretagogue. The above content is from the WeChat subscription number “Zunyi Diabetes Education Window”. You can join by searching for the micro signal “zytnbw” in the WeChat “Add Friend”, or you can directly “sweep” the above WeChat QR code to join.